Finding competent medical care for MCS requires knowing why the system fails most patients, where to find practitioners who understand, and how to show up to appointments with the documentation that shifts the conversation. This page is a practical guide for every step of that process.
If doctors have made you feel like the problem, read this first: you are not. The reason your appointments keep going badly is structural. Environmental medicine is barely taught in medical school, standard allergy panels test for a mechanism MCS does not use, and the routine bloodwork ordered for you was never designed to detect this. Normal results do not mean nothing is wrong — they usually mean the wrong tests were run.
That gap has a real cost. Patients are frequently referred to psychiatry, and once a psychological label enters the record it follows them to every provider afterward. Knowing that is happening is the first step to interrupting it.
This page is the practical route through: which kinds of practitioners actually understand this condition and how to find them, which tests are worth requesting, what to bring to an appointment so you are presenting data rather than describing symptoms, and what to do when a doctor dismisses you anyway.
Most physicians are not failing MCS patients through indifference or bad faith.
They are failing them because their training did not prepare them for what they are seeing — and the default tools of standard medicine are genuinely the wrong tools for this condition.
A 2019 Canadian study found that the majority of family medicine residents lacked specific training in Multiple Chemical Sensitivity diagnosis and management. Environmental medicine is not a standard component of medical education in the United States or most of the English-speaking world. The result is that a patient who presents with complex, multi-system symptoms triggered by chemical exposures encounters a physician who has no diagnostic framework for what they are describing.
The standard workup — CBC, metabolic panel, thyroid function, allergy panel — returns normal results. And normal results, in the absence of training to interpret them, are interpreted as “nothing wrong” rather than “wrong tests ordered.” The tests that are actually informative for MCS (HLA-DR genotyping, CIRS biomarker panel, objective measures like the VCS test and QEESI) are not part of standard practice. Physicians who have not encountered them do not order them.
Standard allergy testing (skin prick and IgE panels) tests for IgE-mediated hypersensitivity reactions. MCS is not an IgE-mediated allergy. It involves TRP receptor sensitization, mast cell activation, and neurological changes — none of which appear on an allergy panel. When allergy testing returns negative for a patient with MCS, this means the wrong test was used. It does not mean the reactions are not real.
When normal tests are combined with the historically prevalent psychological framing of MCS, the referral to psychiatry or psychology follows logically from the framework — even though it is the wrong framework. The patient is referred for anxiety or depression treatment. Antidepressants or CBT are prescribed. These do not address the receptor sensitization or biotoxin burden. The patient does not improve. The medical record now includes a psychological diagnosis that will follow them to every subsequent provider.
Once a patient's medical record includes a psychiatric diagnosis attributed to their MCS symptoms, subsequent physicians encounter that record before they encounter the patient. Confirmation bias does the rest: the physician expects a psychological presentation and interprets the visit accordingly. Breaking this cycle requires presenting objective data that cannot be attributed to anxiety — QEESI scores, HLA-DR results, CIRS biomarkers — before the psychological framing dominates the appointment.
The physicians most likely to help people with MCS are those trained in environmental medicine, those familiar with CIRS and the Shoemaker Protocol, and integrative or functional medicine practitioners who have specifically worked with chemical sensitivity patients.
The International Society for Environmentally Acquired Illness maintains a searchable practitioner directory at iseai.org. Practitioners listed there have demonstrated familiarity with environmentally acquired illness, including MCS and CIRS. This is the most reliable starting point for finding a physician who will approach your condition with the appropriate biological framework.
Board certification in environmental medicine (through the American Board of Environmental Medicine) indicates training specifically in toxicant-related illness. Environmental medicine physicians are equipped to interpret chemical exposure histories, order appropriate testing, and work with MCS patients without defaulting to the psychological framing. They are not universally available, and telehealth appointments have made them more accessible to patients outside major metropolitan areas.
Physicians trained in the Shoemaker Protocol for CIRS (Chronic Inflammatory Response Syndrome) are particularly well-suited to patients with MCS, because the biotoxin pathway is a major underlying mechanism in a significant subset of MCS patients. CIRS-trained practitioners are familiar with HLA-DR genotyping, the CIRS biomarker panel, and the treatment sequencing that addresses the biotoxin burden driving chemical sensitivity.
Integrative and functional medicine practitioners vary widely in their MCS literacy. Some have specific expertise; many do not. The category is broad enough that the label alone is not a sufficient filter. Ask before booking: “Do you have experience treating patients with Multiple Chemical Sensitivity or CIRS?” and “Are you familiar with HLA-DR testing and the Shoemaker Protocol?” These questions will quickly distinguish practitioners with relevant expertise from those without it.
Naturopathic physicians trained in environmental illness can be effective practitioners for MCS, particularly for the nutritional support and detoxification pathway components of management. Their licensing varies by state (some states do not license ND practice), and their scope of practice in ordering laboratory tests also varies. In states where they have full practice rights, NDs with environmental illness training can order the HLA-DR and CIRS panels and manage the non-pharmaceutical aspects of treatment.
The terms “integrative,” “holistic,” and “functional” are used by practitioners across a wide range of competencies and frameworks. Not all of them will be helpful for MCS. Some practitioners in these categories still operate from the psychological attribution framework. Ask the specific questions above before booking any appointment.
Arriving at a medical appointment with objective documentation shifts the dynamic from a patient describing subjective symptoms to a patient presenting measurable data. This distinction matters enormously for how the encounter proceeds.
Document every significant symptom event: date and time, what you were doing, what you were exposed to (including location, products nearby, ventilation), symptoms that followed, severity on a 1–10 scale, and duration. Two weeks of this data creates a pattern that is difficult to attribute to anxiety — it shows chemical exposure as the consistent antecedent and symptom onset as the consistent consequence.
The Quick Environmental Exposure and Sensitivity Inventory (QEESI) is the validated clinical instrument for measuring chemical intolerance severity. It is available free online. Completing it before the appointment and bringing your scores gives the physician a standardized, peer-reviewed measurement of your symptom profile. QEESI scores are published reference data — they are not subjective complaints.
HLA-DR genotyping is a one-time blood test that identifies genetic susceptibility to biotoxin-related illness. If you have already been tested, bring the result. HLA-DR results showing susceptibility haplotypes (particularly the multisusceptible genotype) provide an objective genetic basis for your vulnerability to chemical and biotoxin exposures. See the Mold & MCS page for a full explanation of HLA-DR categories and their implications.
Opening the appointment with a clear frame reduces the probability of the psychological referral loop. Try: “I have documented chemical intolerance — multiple specific exposures trigger predictable symptom patterns. I have QEESI scores showing severe intolerance. I’d like to discuss testing for CIRS and whether HLA-DR genotyping is appropriate.” This names the condition, references objective measurement, and proposes a specific investigative direction before the physician has the opportunity to default to standard psychiatry referral.
Bringing printed abstracts is not adversarial — it is efficient. The Molot 2023 review in Annals of Medicine is the current standard-of-care summary; its conclusion that classifying MCS as a psychosomatic disorder is “no longer scientifically defensible” carries significant clinical weight. The JACI:IP 2024 letter warning against the phobia classification is directly relevant to any physician who applies the psychological framework. Presenting these as “research I’d like to discuss with you” rather than “evidence you are wrong” maintains a collaborative dynamic while establishing the current evidence base.
Standard blood panels, allergy tests, and MRI scans will likely return normal in MCS patients.
This does not rule out MCS or CIRS — it means the standard panels test for different conditions. The tests below are the ones that actually produce meaningful data for this population.
Standard panels — CBC, metabolic panel, thyroid, standard allergy IgE — are likely to be normal in MCS patients. This is not evidence against the diagnosis. It is evidence that MCS does not involve the pathways these tests measure. Standard test normality in MCS is a known feature of the condition, documented in the research literature. When a physician presents normal results as diagnostic, that is the training gap operating in real time.
A one-time blood test identifying genetic haplotypes associated with impaired biotoxin clearance. Around 24% of the population carries the susceptibility genotype; approximately 2% carry the multisusceptible genotype associated with the most severe presentations. A positive susceptibility result provides an objective genetic basis for vulnerability to mold, chemical, and other biotoxin exposures. It is not diagnostic alone, but in combination with symptom history it significantly strengthens the clinical picture. Available through most major reference labs; sometimes requires a physician familiar with CIRS to order.
If HLA-DR shows susceptibility, the CIRS biomarker panel provides a snapshot of the inflammatory cascade. Key markers: TGF-beta-1 (transforming growth factor, elevated in biotoxin illness), MMP-9 (matrix metalloproteinase, marker of neurological and tissue inflammation), C4a (complement split product, elevated in biotoxin exposure), MSH (melanocyte-stimulating hormone, depleted by chronic biotoxin burden), VIP (vasoactive intestinal peptide, involved in immune regulation), and VEGF (vascular endothelial growth factor). These markers are not standard — they require a practitioner familiar with CIRS to order and interpret.
The VCS test measures the visual system’s ability to detect contrast — a function impaired by neurological inflammation from biotoxin burden. It is available free online at survivingmold.com and takes approximately 10 minutes. Abnormal VCS results in the context of symptom history support the CIRS diagnosis and provide a measurable, objective endpoint for treatment progress. It is not conclusive alone, but it is a legitimate screening tool that requires no laboratory and no prescription.
The Quick Environmental Exposure and Sensitivity Inventory is the standard validated instrument for measuring chemical intolerance. It is administered by the patient. The four subscales — Chemical Intolerance, Other Intolerances, Symptom Severity, and Life Impact — produce standardized scores that have published reference ranges for clinical populations. Bringing completed QEESI scores to an appointment converts subjective symptom description into validated quantitative data.
If CIRS is confirmed, testing for MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci) is an important step in the Shoemaker Protocol treatment sequence. MARCoNS is a nasal staph colonization that suppresses MSH, perpetuating the inflammatory cascade. It requires a deep nasal culture (not a standard nasal swab) sent to a lab equipped to perform the sensitivity testing. Eradication of MARCoNS is a step in the Shoemaker Protocol before other treatments can work effectively.
Not all of these tests will be accessible to every patient immediately. Many require a CIRS-familiar practitioner to order. Some require labs that specialize in this testing. Starting with what is accessible — QEESI (free, self-administered), VCS test (free online), and the HLA-DR blood test (most accessible) — and building from there is a realistic approach. Bringing results from accessible tests to a first appointment with a new practitioner establishes the biological framework and facilitates ordering the more specialized tests.
Depending on your symptom pattern, exposure history, and clinical picture, the following tests may add meaningful information. None are universal recommendations — each is most relevant when the clinical picture points in that direction. Discuss with a practitioner familiar with environmental illness before ordering.
Measures specific mycotoxins — ochratoxin A, aflatoxins, trichothecenes, and others — in urine, providing direct evidence of biotoxin burden in the body rather than inferring it from downstream inflammatory markers. This test is particularly useful when CIRS biomarkers are elevated but the source of exposure is unclear, or when tracking clearance during binder therapy to confirm biotoxins are actually being eliminated. Available through specialty labs (RealTime Labs, Great Plains Laboratory). Interpretation requires a practitioner familiar with mycotoxin testing — reference ranges vary by lab and some are still being standardized.
When to consider it: Active or suspected past mold exposure, elevated CIRS biomarkers, plateau in CIRS treatment, or need to confirm biotoxin burden before starting binder therapy.
Standard Ova and Parasites (O&P) testing is completely standard medicine — any physician can order it, and it identifies parasitic infections that are more common than most people realize and that directly drive immune dysregulation and gut inflammation. Comprehensive stool panels (GI-MAP, GI Effects) go further: gut dysbiosis, H. pylori, Clostridioides difficile, leaky gut markers (zonulin, calprotectin), digestive enzyme status, and microbiome disruption. The gut-MCS connection is real — chronic gut inflammation, intestinal permeability, and dysbiosis all amplify systemic reactivity and place additional burden on detoxification pathways.
When to consider it: GI symptoms alongside MCS, food reactivity that worsens over time, fatigue disproportionate to chemical exposures, or CIRS treatment stalling without clear reason.
Urine heavy metals testing — ideally a 6-hour or 24-hour collection — measures the body’s excretion of lead, mercury, arsenic, cadmium, and other metals. For patients where detoxification pathway impairment is a driver, toxic metal accumulation can be a significant and overlooked contributor to overall burden. Hair mineral analysis provides a different window (longer-term deposition) but has more variable interpretation. For patients with significant occupational, military, or residential exposure history, this testing can identify a discrete burden that is addressable through targeted chelation support under medical supervision.
When to consider it: Known occupational or environmental metal exposure (military, industrial, older housing with lead paint or pipes), detox pathway impairment on genetic testing, or recovery plateau that does not respond to biotoxin-targeted treatment.
Standard Lyme testing (ELISA + Western blot) tests only for Borrelia burgdorferi antibodies and misses Bartonella, Babesia, Ehrlichia, Anaplasma, and other common tick-borne co-infections entirely. These co-infections produce overlapping symptoms with MCS and CIRS, and their biotoxins drive the same inflammatory cascade. Multi-susceptible HLA types (particularly 4-3-53) are vulnerable to both mold biotoxins and Lyme-related biotoxins simultaneously. Specialty labs (IGeneX, Galaxy Diagnostics for Bartonella) use more sensitive detection methods. A Lyme-literate physician is required to order and interpret these panels meaningfully.
When to consider it: Multi-susceptible HLA genotype, tick or outdoor exposure history, CIRS treatment plateau, or symptom pattern including joint pain, neurological symptoms, or night sweats alongside chemical sensitivity.
A standard blood panel measuring overall immune function — any physician can order it. While MCS is not IgE-mediated (standard allergy testing is negative in MCS, and that is expected), the broader immunoglobulin panel reveals immune dysregulation that is relevant to MCS and CIRS. IgA deficiency impairs mucosal immune defense and gut barrier function. IgG subclass deficiencies affect the body’s ability to clear specific pathogens and biotoxins. Elevated IgM or IgG patterns can indicate chronic infection burden. These findings do not diagnose MCS, but they map the immune system’s functional state and can guide treatment priorities — particularly in patients where immune dysregulation appears to be amplifying reactivity beyond what biotoxin burden alone explains.
When to consider it: Frequent infections alongside MCS, treatment-resistant immune dysregulation, or preparation for a comprehensive functional medicine workup.
LDN is an off-label, compounded medication that some environmental medicine and MCAS-literate physicians are exploring for patients with significant immune dysregulation driving their MCS. At doses far below standard naltrexone (often beginning at 0.1 mg for MCS patients — well below the typical 1.5–4.5 mg range), it blocks Toll-like receptor 4 (TLR4), reduces microglial activation, and prompts a rebound increase in beta-endorphins that helps recalibrate immune reactivity. A published case study documented improved odour and food sensitivities, reduced pain, better sleep, and a 17% reduction in MCAS severity scores after 6 weeks of ultra-low-dose naltrexone. It is not a first-line intervention and is not suitable for everyone: it cannot be taken with opioid pain medications, requires a compounding pharmacy, and must be introduced very slowly given MCS sensitivity. It is a conversation to have with a practitioner experienced in environmental illness — not a self-directed protocol. See our Getting Better page, MCAS pathway section, for more context on where LDN fits in mast cell management.
Dismissal is common. Knowing what to do when it happens — both in the moment and after — reduces its impact and protects your interests.
After an appointment where your condition is dismissed or attributed to psychology, send a follow-up email to the practice summarizing what was said. “Following our appointment on [date], I want to confirm my understanding that you concluded my symptoms are attributable to anxiety rather than a physiological cause. I disagree with this conclusion for the following reasons...” This creates a paper record of the interaction and often changes the quality of subsequent appointments. Practices respond differently to documented disagreements than to undocumented ones.
A dismissing physician may refuse a referral, but the request and the refusal are both documented if made in writing. You have the right to request specialist referral. If the physician declines, ask them to document the reason for the decline in your chart. This establishes a record and also creates an accountability mechanism that can change behavior.
If a physician attributes your MCS symptoms to stress or anxiety, ask: “What objective evidence supports that attribution, and what would you need to see to consider a physiological explanation?” This does not require the physician to have the answer. It documents that the attribution is not evidence-based and identifies what data might change the conversation. You have the right to a second opinion. You have the right to disagree with a diagnosis in your own medical record, and to have your disagreement documented.
Recommending graded chemical exposure therapy — the practice of deliberately exposing an MCS patient to increasing concentrations of their triggers as a desensitization protocol — is not evidence-based for MCS and can cause active harm by increasing sensitization. If a physician recommends this, you have grounds to file a complaint with your state medical board. Medical board complaints are not filed for differences of opinion; they are appropriate when recommended treatment is below the standard of care or causes demonstrable harm.
Hospitals are among the highest-exposure environments a person with MCS can enter — cleaning chemicals, air fresheners, fragranced staff products, latex, fresh paint, and recirculated air are present throughout most hospital facilities. Preparation reduces risk substantially.
For any non-emergency hospital visit — scheduled surgery, planned procedure, specialist appointment — contact the facility in advance. Notify the patient services or patient advocacy department of your MCS diagnosis and the specific accommodations you require: fragrance-free room (no air fresheners, deodorizers, or scented cleaning products), fragrance-free products used by all staff who enter your room, and adequate ventilation. Confirm these accommodations in writing. The ADA requires reasonable accommodations for disability; MCS qualifies. See the Disability Rights page for the legal framework.
Your own pillow in a fragrance-free case eliminates one common exposure source. If you have specific fragrance-free personal care products, bring them and make sure staff know to use them rather than standard hospital products. If you have an air purifier that is portable, bringing a small activated carbon unit can significantly reduce VOC load in a hospital room — most facilities will permit this with appropriate explanation.
Avoid elective procedures in newly renovated hospital wings — fresh paint, new flooring adhesive, and new furniture off-gassing create extreme VOC loads that can persist for weeks. Request an older wing when scheduling, and ask how recently your assigned room or unit was renovated. Ask about the HVAC system — dedicated fresh air supply to a room, rather than recycled hospital air, is substantially better for MCS patients.
A support person who is familiar with your MCS protocols and who can advocate on your behalf when you are incapacitated, sedated, or in acute distress is one of the most important safety measures for hospital care. This person should know your specific triggers, know what fragrance-free means in practice, and be empowered to intervene if staff enter your room with fragranced products. Prepare a written card summarizing your key needs that your advocate can hand to staff without requiring explanation in every interaction.
Emergency situations remove the ability to self-advocate. Preparation before an emergency allows your needs to be communicated when you cannot communicate them yourself.
A medical alert bracelet or card that states your MCS diagnosis communicates critical information before any verbal exchange. The bracelet or card should read: Multiple Chemical Sensitivity. Please use unscented products only. No air fresheners or fragranced cleaning products. Keep area well-ventilated. Medical alert jewelry is recognized by emergency responders and triggers the appropriate information-gathering protocols.
Keep a card in your wallet — the size of a business card — that emergency responders can find and read quickly. It should include: your diagnosis (Multiple Chemical Sensitivity), your primary triggers, your primary MCS contact person and their phone number, the name and contact of any MCS-literate physician you see, and the key instruction: unscented products, no air fresheners, adequate ventilation. Laminate it. Update it if your practitioners change.
The person listed as your ICE (In Case of Emergency) contact should be briefed on your MCS protocols before any emergency occurs. They should know your specific triggers, what fragrance-free means in practice, which hospitals in your area have been most accommodating of MCS needs, and the name of your MCS practitioner. If possible, they should have a written summary they can hand to emergency personnel. A person who has never heard of MCS cannot effectively advocate for you in an emergency on your behalf.
If you are experiencing a medical emergency at home, a family member or support person who calls ahead to the hospital or communicates with paramedics about your MCS before you arrive can significantly reduce the exposure load you encounter on arrival. Paramedics are trained to receive medical history from bystanders. A support person saying “she has Multiple Chemical Sensitivity — please use unscented products and avoid air fresheners in the ambulance” before transport begins is more effective than trying to communicate this yourself while in acute distress.
After any emergency medical encounter, document what exposures occurred and what symptoms followed. This documentation becomes part of the case history that helps you prepare better for future encounters — and it may be relevant to disability claims or medical record corrections. If a care provider used fragranced products after being told not to, that is a documented ADA accommodation failure. You are not required to accept it silently, and a complaint filed afterward is legitimate.
What is Multiple Chemical Sensitivity? MCS is a chronic, physiological condition causing reactions to everyday low-level…
Why is MCS so confusing? Different triggers, thresholds, and reactions per person; hills and valleys; and why "this cure…
The full by-system symptom list for Multiple Chemical Sensitivity: neurological, respiratory, fatigue, gastrointestinal,…
How does MCS work in the body? The five documented mechanisms: mast cell activation, TRPV1/TRPA1 receptor sensitization,…
Learn about TILT — Toxicant-Induced Loss of Tolerance — the two-stage mechanism behind Multiple Chemical Sensitivity…
What is electromagnetic hypersensitivity (EHS)? Symptoms, the documented overlap with MCS, peer-reviewed research on EMF…
How fibromyalgia and Multiple Chemical Sensitivity overlap: shared central sensitization, the documented comorbidity (55…
Work out what size air purifier you actually need: room volume, air changes per hour, required CADR in CFM, and the carb…
EDS is genetic — chemicals do not cause it. But EDS and Mast Cell Activation Syndrome (MCAS) frequently co-occur, and …
How ME/CFS (chronic fatigue syndrome) and MCS overlap: shared neuroinflammation, oxidative stress, and central sensitiza…
Free TILT Self-Assessment including the BREESI screener and QEESI — the gold standard for identifying chemical intoler…
Free printable MCS patient toolkit: doctor-visit packet, accommodation letters, symptom tracker, wallet card, one-page e…
How mold exposure triggers chemical sensitivity through CIRS and TILT. Biotoxin pathways, HLA genetics, testing, remedia…
The deep science behind CIRS: why certain HLA-DR gene types cannot clear mold biotoxins, the recirculation loop, HLA hap…
CDC surveillance found 449 invasive mold disease cases and 45% 90-day all-cause mortality. What the study actually shows…
The current state of MCS research: what the 2023 Molot review changed, TRP receptor modulation, biotoxin elimination adv…
Is Multiple Chemical Sensitivity psychological or physical? A plain-language comparison of the 2024 Brain Sciences psych…
The documented history of Multiple Chemical Sensitivity: from Theron Randolph's 1950s clinical observations through the …
77 peer-reviewed studies on chemical exposure, MCS, indoor air quality, and human health. Organised by category with ful…
Can you recover from MCS? Many people have. Testing, treatment pathways, and actionable steps for CIRS treatment, mast c…
The priority-ordered tests that identify what is driving your MCS: HLA-DR genotyping, CIRS biomarkers, mast cell markers…
Evidence-based strategies for managing MCS toxic loads. Detoxification support, vagus nerve techniques, air filtration, …
Why people with MCS often react to food as well as chemicals. Histamine intolerance, mast cell activation, DAO enzyme de…
Comprehensive guide to MCS triggers — chemicals, foods, drugs — with practical alternatives and the Personal Precaut…
Indoor air can be 5x more polluted than outdoor air. Assessment tools, filtration guidance, safe building materials, and…
Can ozone remove new-couch or new-carpet VOC smell? No — it makes new pollutants. The safe fix: ventilation, bake-out,…
An honest, MCS-focused look at WellisAir and hydroxyl air-cleaning devices — what they do, what they don't, and whethe…
The canonical MCS air filter guide: why activated carbon is essential, which purification technologies to avoid, a 7-poi…
An honest, MCS-calibrated guide to fragrance-free cleaners and laundry detergent: why "unscented" is not the same as "fr…
Shampoo, moisturizer, deodorant, and sunscreen for MCS: vetted fragrance-free brands, why deodorant is the hardest categ…
The honest MCS guide to zero-VOC paint: what GREENGUARD Gold actually means (and doesn't), vetted MCS-specialty brands, …
Personal air protection for MCS away from home: a respirator with multi-gas P100 cartridges, a carbon disposable mask, a…
What makes a mattress safe or unsafe for people with MCS? GREENGUARD Gold explained, latex risk, mold prevention, and an…
A practical guide to mold testing and remediation for people with MCS. Which tests are useful, how to interpret results,…
MCS disability protections under the ADA, Fair Housing Act, Social Security, and international law. Workplace accommodat…
How to navigate public spaces, workplaces, travel, hotels, and everyday errands with MCS. Preparation strategies, legal …
The emotional consequences of MCS are real, documented, and devastating. Grief, identity loss, isolation, financial terr…
Does MCS run in families? How to identify chemical sensitivity in children, navigate school accommodations, protect chil…
How military toxic exposures connect to MCS. VA disability claims, the PACT Act, medical evidence, and support resources…
Real accounts of developing MCS, navigating diagnosis, reorganizing a life, and finding a way forward. Three documented …
A guide for partners, family, and friends of people with MCS. What is happening in their body, how to make visits safe, …
Plain-English definitions of 50+ medical and scientific terms used in MCS and CIRS. TILT, HLA-DR, MCAS, biotoxins, QEESI…
Answers to the most common questions about Multiple Chemical Sensitivity — diagnosis, treatment options, disability ri…